GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs #GSK #Threat #039Double #Whammy039…
Tag: GSK
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities…
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK#SHAREHOLDER #REMINDER #Faruqi…
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in…
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities…
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities…
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities…
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK#ONGOING #DEADLINE…
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
GSK plc (NYSE:GSK) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company…
GSK Enters Agreement to Acquire IDRx, Inc. By Investing.com
Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal…
FDA grants breakthrough status to GSK cancer drug By Investing.com
LONDON – GSK plc (LSE/NYSE: GSK) has received Breakthrough Therapy Designation from the US Food and…